RetroSense Therapeutics Completes Low Dose Cohort in Clinical Trial of Novel Gene Therapy Application of Optogenetics

ANN ARBOR, Mich.--(BUSINESS WIRE)--RetroSense Therapeutics LLC, a privately-held biopharmaceutical company, today announced that the low dose cohort of patients has been safely dosed in the initial clinical trial to evaluate the safety of RST-001. No inflammation or ocular adverse events were seen in any of these patients, and biological activity has been confirmed. The study is titled Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Uniocular Intravitreal RST-001 in